<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740100</url>
  </required_header>
  <id_info>
    <org_study_id>PQR309-009</org_study_id>
    <nct_id>NCT03740100</nct_id>
  </id_info>
  <brief_title>Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations</brief_title>
  <acronym>HNSCC</acronym>
  <official_title>Open-label, Single Arm, Two-stage Study, Evaluating the Efficacy and Safety of Bimiralisib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (HNSCC) Harboring NOTCH1 Loss of Function (LOF) Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PIQUR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PIQUR Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell&#xD;
      Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition&#xD;
      (phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibition).&#xD;
&#xD;
      The current study enrolls patients with refractory and / or metastatic Head and Neck&#xD;
      Squameous Cell Carcinoma based on the mutational status of their disease to assess the&#xD;
      response to treatment with bimiralisib, an orally available pan-PI3K/mTOR inhibitor&#xD;
      (phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibitor).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Actual">August 5, 2020</completion_date>
  <primary_completion_date type="Actual">August 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Oral administration</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of change of tumor size from baseline</measure>
    <time_frame>Every 6 weeks until all patients have been treated for 6 months</time_frame>
    <description>Radiological tumor assessments will be performed by computed tomography (CT) or magnetic resonance imaging (MRI) according to a standard protocol</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>Open single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bimiralisib capsules orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimiralisib</intervention_name>
    <description>Bimiralisib capsules</description>
    <arm_group_label>Open single arm</arm_group_label>
    <other_name>PQR309, PI3K/mTOR inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytological confirmed diagnosis of Head and Neck Squameous Cell&#xD;
             Carcinoma, for which no standard curative or life prolonging therapy is available&#xD;
&#xD;
          2. Available CLIA-certified sequencing results of the NOTCH gene in Head and Neck&#xD;
             Squameous Cell Carcinoma (HNSCC) tumor material. The tumor must harbor a NOTCH1 LOF&#xD;
             mutation as confirmed by central review (MD Anderson Cancer Center, MDACC)&#xD;
&#xD;
          3. ECOG performance status of ≤ 2&#xD;
&#xD;
          4. Adequate bone marrow, liver, and renal functions&#xD;
&#xD;
          5. Measurable disease according to RECIST version 1.1&#xD;
&#xD;
          6. Patients of reproductive potential must agree to use effective contraception from&#xD;
             screening until 90 days after discontinuing study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has received any anti-cancer treatment including hormonal and investigational agents&#xD;
             within 21 days prior to first dose of bimiralisib.&#xD;
&#xD;
          2. Major surgery within 28 days prior to first dose of bimiralisib or persisting side&#xD;
             effects that have not improved to NCI-CTCAE grade 1 or better.&#xD;
&#xD;
          3. Pregnant or nursing (lactating) women.&#xD;
&#xD;
          4. Poorly controlled diabetes mellitus, steroid-induced diabetes mellitus&#xD;
&#xD;
          5. Has other active malignancies that require systemic treatment.&#xD;
&#xD;
          6. Has a known history of HIV infection&#xD;
&#xD;
          7. Any of the following cardiac abnormalities:&#xD;
&#xD;
               -  History of, or current, documented congestive heart failure (New York heart&#xD;
                  association functional classification iii - iv), documented cardiomyopathy&#xD;
&#xD;
               -  Symptomatic (NYHA class II or higher) left ventricular ejection fraction (LVEF) &lt;&#xD;
                  40% as determined by multiple gated acquisition (MUGA) scan or echocardiogram&#xD;
                  (echo)&#xD;
&#xD;
               -  Myocardial infarction ≤ 6 months prior to enrolment&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Symptomatic pericarditis&#xD;
&#xD;
          8. Impaired gastrointestinal (GI) function or GI disease that may significantly alter the&#xD;
             absorption of study drug.&#xD;
&#xD;
          9. Patient has a history of non-compliance to medical regimen or inability to grant&#xD;
             consent.&#xD;
&#xD;
         10. Medically documented history of an active major depressive episode, bipolar disorder&#xD;
             (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt&#xD;
             or ideation, or homicidal ideation (immediate risk of doing harm to others) or ≥ CTCAE&#xD;
             grade 3 anxiety&#xD;
&#xD;
         11. History of interstitial pneumonitis or patients who require chronic oxygen&#xD;
             supplementation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faye M Johnson, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center Recruiting, Houston, Texas, US 77030</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Notch 1 loss of function mutation</keyword>
  <keyword>PI3K/mTOR Inhibitor</keyword>
  <keyword>Refractory metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 7, 2021</submitted>
    <returned>September 28, 2021</returned>
    <submitted>September 28, 2021</submitted>
    <returned>October 25, 2021</returned>
    <submitted>November 9, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

